selumetinib
AstraZeneca’s selumetinib fails to meet primary endpoint in lung cancer trial again
August 9, 2016Manufacturing and Production AstraZeneca, failure, non-small cell lung cancer, phase III, selumetinib, trial failure
AstraZeneca has announced that its MEK 1/2 inhibitor, selumetinib, failed to meet its primary endpoint of progression free survival in …
AstraZeneca bags another FDA orphan status in cancer
April 17, 2015Sales and Marketing AstraZeneca, Cancer, FDA, GlaxoSmithKline, mekinist, melanoma, oncology, selumetinib, trametinib
The FDA has granted AstraZeneca’s cancer medicine selumetinib orphan drug designation for the treatment of uveal melanoma. The company will …
AZ begins late-stage trial of new cancer drug
October 22, 2013Research and Development, Sales and Marketing AstraZeneca, Cancer, NSCLC, selumetinib
AstraZeneca has begun a Phase III study for its investigational lung cancer pill selumetinib in patients with a genetic sub-type …
Trial disappointment for AZ lung cancer drug
October 3, 2011Research and Development, Sales and Marketing AstraZeneca, selumetinib
AstraZeneca’s lung cancer drug selumetinib has failed to hit its primary endpoint in a Phase II trial. The trial compared …
